Search

Your search keyword '"Capuano, Annalisa"' showing total 1,160 results
Start Over Author "Capuano, Annalisa"
1,160 results on '"Capuano, Annalisa"'

2. The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O

Author

Dell’Anno, Irene, Dondi, Leonardo, Esposito, Immacolata, Mascolo, Annamaria, Capuano, Annalisa, de Marchi, Giulia, Cristinziano, Adriano, Tarantino, Domenico, Pani, Marcello, Masini, Carla, Donati, Caterina, Rossin, Elisabetta, Serafini, Antonio, Bagaglini, Gabriele, Bonanni, Gabriella, Gregori, Tommaso, Cavaliere, Arturo, Matocci, Roberta, D’Arpino, Alessandro, Martini, Nello, and Piccinni, Carlo

Published
2024
Full Text
View/download PDF

3. Treatment of acute pharyngitis in children: an Italian intersociety consensus (SIPPS-SIP-SITIP-FIMP-SIAIP-SIMRI-FIMMG)

Author

Chiappini, Elena, Simeone, Giovanni, Bergamini, Marcello, Pellegrino, Roberta, Guarino, Alfredo, Staiano, Annamaria, Esposito, Susanna, Gattinara, Guido Castelli, Vecchio, Andrea Lo, Stefani, Stefania, Iacono, Iride Dello, Scotese, Immacolata, Tezza, Giovanna, Dinardo, Giulio, Riccio, Simona, Pellizzari, Sofia, Iavarone, Sonia, Lorenzetti, Giulia, Venturini, Elisabetta, Donà, Daniele, Pierantoni, Luca, Doria, Mattia, Garazzino, Silvia, Midulla, Fabio, Cricelli, Claudio, Terracciano, Luigi, Capuano, Annalisa, Bruzzese, Eugenia, Ghiglioni, Daniele, Fusani, Lara, Fusco, Eleonora, Biasci, Paolo, Reggiani, Lamberto, Matera, Luigi, Mancino, Enrica, Barbieri, Elisa, D’Avino, Antonio, Cursi, Laura, Sullo, Maria Giuseppa, Scotti, Silvestro, Marseglia, Gian Luigi, Di Mauro, Giuseppe, Principi, Nicola, Galli, Luisa, and Verga, Maria Carmen

Published
2024
Full Text
View/download PDF

5. Neutral endopeptidase (neprilysin)

Author

Mascolo, Annamaria, primary, Sportiello, Liberata, additional, Riemma, Maria Antonietta, additional, De Angelis, Antonella, additional, Capuano, Annalisa, additional, and Berrino, Liberato, additional

Published
2024
Full Text
View/download PDF

8. Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction: A literature systematic review

Author

Barbieri, Michelangela, Chiodini, Paolo, Di Gennaro, Piergiacomo, Hafez, Gaye, Liabeuf, Sophie, Malyszko, Jolanta, Mani, Laila-Yasmin, Mattace-Raso, Francesco, Pepin, Marion, Perico, Norberto, Simeoni, Mariadelina, Zoccali, Carmine, Tortorella, Giovanni, Capuano, Annalisa, Remuzzi, Giuseppe, Capasso, Giovambattista, and Paolisso, Giuseppe

Published
2024
Full Text
View/download PDF

14. Correction: Inter-society consensus for the use of inhaled corticosteroids in infants, children and adolescents with airway diseases

Author

Duse, Marzia, Santamaria, Francesca, Verga, Maria Carmen, Bergamini, Marcello, Simeone, Giovanni, Leonardi, Lucia, Tezza, Giovanna, Bianchi, Annamaria, Capuano, Annalisa, Cardinale, Fabio, Cerimoniale, Giovanni, Landi, Massimo, Malventano, Monica, Tosca, Mariangela, Varricchio, Attilio, Zicari, Anna Maria, Alfaro, Carlo, Barberi, Salvatore, Becherucci, Paolo, Bernardini, Roberto, Biasci, Paolo, Caffarelli, Carlo, Caldarelli, Valeria, Capristo, Carlo, Castronuovo, Serenella, Chiappini, Elena, Cutrera, Renato, De Castro, Giovanna, De Franciscis, Luca, Decimo, Fabio, Iacono, Iride Dello, Diaferio, Lucia, Di Cicco, Maria Elisa, Di Mauro, Caterina, Di Mauro, Cristina, Di Mauro, Dora, Di Mauro, Francesco, Di Mauro, Gabriella, Doria, Mattia, Falsaperla, Raffaele, Ferraro, Valentina, Fanos, Vassilios, Galli, Elena, Ghiglioni, Daniele Giovanni, Indinnimeo, Luciana, Kantar, Ahmad, Lamborghini, Adima, Licari, Amelia, Lubrano, Riccardo, Luciani, Stefano, Macrì, Francesco, Marseglia, Gianluigi, Martelli, Alberto Giuseppe, Masini, Luigi, Midulla, Fabio, Minasi, Domenico, Miniello, Vito Leonardo, Del Giudice, Michele Miraglia, Morandini, Sergio Renzo, Nardini, Germana, Nocerino, Agostino, Novembre, Elio, Pajno, Giovanni Battista, Paravati, Francesco, Piacentini, Giorgio, Piersantelli, Cristina, Pozzobon, Gabriella, Ricci, Giampaolo, Spanevello, Valter, Turra, Renato, Zanconato, Stefania, Borrelli, Melissa, Villani, Alberto, Corsello, Giovanni, Di Mauro, Giuseppe, and Peroni, Diego

Published
2022
Full Text
View/download PDF

15. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs

Author

Del Re, Marzia, Crucitta, Stefania, Paolieri, Federico, Cucchiara, Federico, Verzoni, Elena, Bloise, Francesco, Ciampi, Raffaele, Mercinelli, Chiara, Capuano, Annalisa, Sportiello, Liberata, Martinetti, Antonia, Procopio, Giuseppe, Galli, Luca, Porta, Camillo, Bracarda, Sergio, and Danesi, Romano

Published
2022
Full Text
View/download PDF

17. Risk of Rhabdomyolysis Associated with Dexmedetomidine Use over the Past 10 Years: Insights from the EudraVigilance Database.

Author

Balzano, Nunzia, Mascolo, Annamaria, Di Napoli, Raffaella, Colapietra, Federica, Di Domenico, Marina, Capuano, Annalisa, and Gargano, Francesca

Subjects
DEXMEDETOMIDINE, RESPIRATORY insufficiency, SYMPTOMS, DATABASES, PROPOFOL
Abstract

Dexmedetomidine, a selective α2-adrenergic agonist, is favoured in intensive care for its minimal respiratory depression. This study evaluated the reporting frequency of rhabdomyolysis with dexmedetomidine compared to midazolam and propofol using the European pharmacovigilance database Eudravigilance. We conducted an observational, retrospective analysis of Individual Case Safety Reports (ICSRs) from 1 January 2013, to 31 December 2023. Primary and secondary outcomes included the reporting frequencies of rhabdomyolysis and its indicative signs and symptoms, respectively. We retrieved 19,268 ICSRs, of which 364 reported rhabdomyolysis associated with dexmedetomidine (3.8%), midazolam (10.2%), propofol (76.9%), or combinations thereof (9.1%). Dexmedetomidine showed a significantly lower reporting frequency of rhabdomyolysis compared to propofol (ROR, 0.32; 95% CI, 0.19–0.55) but no significant difference compared to midazolam. Subgroup analyses revealed higher frequencies in males, especially with propofol. Despite limitations such as underreporting, our findings suggest dexmedetomidine poses a lower rhabdomyolysis risk than propofol, supporting its safe use for sedation in high-risk patients. It is important to note that due to the retrospective design of this study our findings are indicative of correlations rather than causation. Continuous monitoring and further studies are recommended to validate these results. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. SMS-Based Active Surveillance of Adverse Events following Immunization in Children: The VigiVax Study.

Author

Gonella, Laura Augusta, Moretti, Francesca, Capuano, Annalisa, De Sarro, Caterina, Ferrara, Lorenza, Geninatti, Elisabetta, Guarnieri, Greta, Hysolakoj, Xhikjana, Lalli, Margherita, Leoni, Olivia, Mangano, Antea Maria Pia, Marani Toro, Patrizia, Mecchia, Viviana, Merlano, Maria Caterina, Palleria, Caterina, Potenza, Anna Maria, Rossi, Paola, Rossi, Marco, Sanità, Francesca, and Sapigni, Ester

Subjects
IMMUNIZATION of children, VACCINE safety, DIGITAL technology, ELECTRONIC surveillance, IMMUNIZATION
Abstract

Underreporting is the main limitation of spontaneous reporting systems. This cohort-event monitoring study aims to examine the potential of short message service (SMS)-based surveillance compared to traditional surveillance systems. Using VigiVax software, parents of vaccinated children aged two years or younger, in the period March 2021–May 2022, received a single SMS inquiry about adverse events following immunization (AEFI). Responses were collected, validated by health operators and integrated with the information on electronic immunization registries. AEFI reports were automatically submitted to the Italian Pharmacovigilance system. Among 254,160 SMS messages sent, corresponding to 451,656 administered doses (AD), 71,643 responses were collected (28.2% response rate), and 21,231 of them (8.3%) reported AEFI. After a seriousness assessment based on clinical criteria, 50 reports (0.24%) were classified as serious. Among these, a causality assessment identified 31 reports at least potentially related to the vaccination (RR: 6.86/100,000 AD). Febrile seizures following MMRV (measles, mumps, rubella, varicella) vaccination accounted for 11 of these 31 cases, with an incidence of 32 per 100,000 AD. No fatal outcomes were reported. Our findings support the highly favorable risk profile of pediatric vaccinations and the possibility to improve spontaneous reporting through the integration of digital technologies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma

Author

Crucitta, Stefania, primary, Cucchiara, Federico, additional, Marconcini, Riccardo, additional, Bulleri, Alessandra, additional, Manacorda, Simona, additional, Capuano, Annalisa, additional, Cioni, Dania, additional, Nuzzo, Amedeo, additional, de Jonge, Evert, additional, Mathjissen, Ron H. J., additional, Neri, Emanuele, additional, van Schaik, Ron H. N., additional, Fogli, Stefano, additional, Danesi, Romano, additional, and Del Re, Marzia, additional

Published
2024
Full Text
View/download PDF

23. Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System

Author

Ruggiero, Rosanna, primary, Balzano, Nunzia, additional, Nicoletti, Maria Maddalena, additional, di Mauro, Gabriella, additional, Fraenza, Federica, additional, Campitiello, Maria Rosaria, additional, Rossi, Francesco, additional, and Capuano, Annalisa, additional

Published
2024
Full Text
View/download PDF

24. Artificial intelligence for optimizing benefits and minimizing risks of pharmacological therapies: challenges and opportunities

Author

Crisafulli, Salvatore, primary, Ciccimarra, Francesco, additional, Bellitto, Chiara, additional, Carollo, Massimo, additional, Carrara, Elena, additional, Stagi, Lisa, additional, Triola, Roberto, additional, Capuano, Annalisa, additional, Chiamulera, Cristiano, additional, Moretti, Ugo, additional, Santoro, Eugenio, additional, Tozzi, Alberto Eugenio, additional, Recchia, Giuseppe, additional, and Trifirò, Gianluca, additional

Published
2024
Full Text
View/download PDF

27. Efficacy of erythropoietin as a neuroprotective agent in CKD-associated cognitive dysfunction:A literature systematic review

Author

Barbieri, Michelangela, Chiodini, Paolo, Di Gennaro, Piergiacomo, Hafez, Gaye, Liabeuf, Sophie, Malyszko, Jolanta, Mani, Laila Yasmin, Raso, Francesco Mattace, Pepin, Marion, Perico, Norberto, Simeoni, Mariadelina, Zoccali, Carmine, Tortorella, Giovanni, Capuano, Annalisa, Remuzzi, Giuseppe, Capasso, Giovambattista, Paolisso, Giuseppe, Barbieri, Michelangela, Chiodini, Paolo, Di Gennaro, Piergiacomo, Hafez, Gaye, Liabeuf, Sophie, Malyszko, Jolanta, Mani, Laila Yasmin, Raso, Francesco Mattace, Pepin, Marion, Perico, Norberto, Simeoni, Mariadelina, Zoccali, Carmine, Tortorella, Giovanni, Capuano, Annalisa, Remuzzi, Giuseppe, Capasso, Giovambattista, and Paolisso, Giuseppe

Abstract

Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous system disorders. Recombinant human EPO (rHuEPO), commonly used to treat anemia in CKD patients, could be a neuroprotective agent. In this systematic review, we aimed to assess the published studies investigating the cognitive benefits of rHuEPO treatment in individuals with reduced kidney function. We comprehensively searched Pubmed, Cochrane Library, Scopus, and Web of Science databases from 1990 to 2023. After selection, 24 studies were analyzed, considering study design, sample size, participant characteristics, intervention, and main findings. The collective results of these studies in CKD patients indicated that rHuEPO enhances brain function, improves performance on neuropsychological tests, and positively affects electroencephalography measurements. These findings suggest that rHuEPO could be a promising neuroprotective agent for managing CKD-related cognitive impairment.

Published
2024

29. The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O.

Author

Dell'Anno, Irene, Dondi, Leonardo, Esposito, Immacolata, Mascolo, Annamaria, Capuano, Annalisa, de Marchi, Giulia, Cristinziano, Adriano, Tarantino, Domenico, Pani, Marcello, Masini, Carla, Donati, Caterina, Rossin, Elisabetta, Serafini, Antonio, Bagaglini, Gabriele, Bonanni, Gabriella, Gregori, Tommaso, Cavaliere, Arturo, Matocci, Roberta, D'Arpino, Alessandro, and Martini, Nello

Subjects
ANTINEOPLASTIC agents, DRUG approval, DRUG utilization, PHARMACEUTICAL industry, TRASTUZUMAB
Abstract

Background: Compassionate drug use (CDU) provides early access to not yet authorised medicines and is funded by pharmaceutical companies. The observational retrospective study Compass-O monitored the CDU of onco-haematological drugs, managed by seven Italian units for cytotoxic drug preparations (Unità Farmaci Antiblastici [UFA]), between 1 January, 2016 and 31 December, 2021. Objective: We aimed to evaluate the CDU of onco-haematological drugs managed by seven Italian UFA, between 2016 and 2021. Methods: The seven UFA provided anonymised data concerning CDU approved in the study period. The early access and potential cost savings for the National Health System (Servizio Sanitario Nazionale [SSN]) were analysed for CDU concerning drug-therapeutic indication combinations with complete data and reimbursed by SSN up to December 2023 (date of study execution), according to the executive decision of the Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]). Both analyses distinguished solid/liquid tumours and categorised the combinations as innovative (fully/conditionally) or non-innovative based on AIFA assessments. Results: Compass-O collected 783 CDU authorisations, with 572 (73.1%) analysable in terms of early access and cost savings. On average, early access amounted to 514 days and the total cost savings was €376,115,801. Compassionate drug use approvals involved mainly solid tumours (93.7% vs 6.3% for liquid tumours), and the combination of trastuzumab emtansine-breast cancer was the most dispensed (n = 73; early access = 426 days; potential cost savings: €610,388). Out of 572 CDU approvals, 200 (35%) were innovative drug-therapeutic indication combinations, with 598 days of early access and a total potential saving of €113,124,069. Conclusions: The study Compass-O showed a significant economic burden of CDU and a relevant need for early access, particularly for innovative drugs. However, there is currently no structured monitoring of CDU in Italy, suggesting the need for a national observatory, of which Compass-O can be the pilot phase. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system.

Author

Scavone, Cristina, Anatriello, Antonietta, Baccari, Isabella, Cantone, Andrea, Di Giulio Cesare, Daniele, Bernardi, Francesca Futura, Moreggia, Ornella, Liguori, Valerio, Andreone, Vincenzo, Maniscalco, Giorgia Teresa, and Capuano, Annalisa

Subjects
MULTIPLE sclerosis, CHRONIC lymphocytic leukemia, DRUG administration, FEVER, AGE groups
Abstract

Introduction: In 2021 ofatumumab, a recombinant human anti-CD20 monoclonal antibody (mAb) already authorized for the treatment of chronic lymphocytic leukemia, received the marketing approval for the treatment of relapsing forms of multiple sclerosis (MS). Differently from ocrelizumab, that is administered intravenously, ofatumumab if the first anti-CD20 mAb to be administered subcutaneously without a premedication. Methods and objectives: In this study we aimed to describe and compare the main characteristics of Individual Case Safety Reports (ICSRs) describing the occurrence of Injective Related Reactions (IRRs) following the treatment with ocrelizumab and ofatumumab reported in the Eudravigilance (EV) database during years 2021–2023. Results: A total of 860 ICSRs with either ofatumumab and ocrelizumab as suspected drug were retrieved from Eudravigilance, of which 51% associated with ofatumumab and 49% with ocrelizumab. The majority of patients who experienced IRRs following ocrelizumab belonged to the age group of 18– 64  years (73%), while the age-group was mostly not specified (55%) in ICSRs reporting ofatumumab as suspected. The distribution of gender was almost similar in the two groups, with the majority of ICSRs related to female patients. “Pyrexia” was the Preferred Term (PT) most reported for ofatumumab, while “Infusion related reaction” were more frequently reported with ocrelizumab. Premedication drugs were reported in 148 ICSRs. Out of 89 ICSRs for which the Time to Event (TTE) was calculated, 74 reported IRRs that occurred the same day of the drug administration. Discussion: Based on the results of this study, although a risk of of atumumab-induced IRRs cannot be excluded, it should be considered as manageable considering that the drug seems to be mostly associated with the occurrence of fever. Thus, it is important to continue to closely monitor the use of these in clinical practice to improve the knowledge on their long-term safety. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series.

Author

Scavone, Cristina, Liguori, Valerio, Adungba, Olusola Jephthah, Cesare, Daniele Di Giulio, Sullo, Maria Giuseppa, Andreone, Vincenzo, Sportiello, Liberata, Maniscalco, Giorgia Teresa, and Capuano, Annalisa

Subjects
BLOOD diseases, IDIOPATHIC thrombocytopenic purpura, AUTOIMMUNE hemolytic anemia
Abstract

Introduction: Disease modifying therapies (DMTs) used to treat multiple sclerosis (MS) can be associated to the occurrence of hematological disorders. This systematic review aims to provide an overview of these events occurring in reallife conditions, by describing case reports and series published in the literature. Methods: A literature search of all publications up to January 5th 2024 on the Medline and Embase databases was carried out. The results were presented both in the text and in tables. Results: Sixty-seven case reports/series were included in this review, of which more than half related to alemtuzumab, natalizumab and ocrelizumab. The publication date of included studies ranged from 2006 to 2024. The majority of case reports and series described the occurrence of late-onset hematological disorders (events that occurred more than 30 days after the first DMT administration), mainly represented by case of neutropenia, autoimmune hemolytic anemia and immune thrombocytopenia. All cases reported a favorable outcome, apart one case report that described a fatal case. Among included cases, 4 articles, all related to natalizumab, described the occurrence of myeloid disorders in 13 newborns from mother receiving the DMT. Discussion: Considering the limitations identified in the majority of included studies, further ad hoc studies are strongly needed to better evaluate the hematological disorders of DMTs. Meantime, the strict monitoring of treated patients for the occurrence of these toxicities should be highly recommended. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice

Author

Longo, Miriam, primary, Caruso, Paola, additional, Scappaticcio, Lorenzo, additional, Maiorino, Maria Ida, additional, Bellastella, Giuseppe, additional, Capuano, Annalisa, additional, Esposito, Katherine, additional, and Giugliano, Dario, additional

Published
2024
Full Text
View/download PDF

35. Inter-society consensus for the use of inhaled corticosteroids in infants, children and adolescents with airway diseases

Author

Duse, Marzia, Santamaria, Francesca, Verga, Maria Carmen, Bergamini, Marcello, Simeone, Giovanni, Leonardi, Lucia, Tezza, Giovanna, Bianchi, Annamaria, Capuano, Annalisa, Cardinale, Fabio, Cerimoniale, Giovanni, Landi, Massimo, Malventano, Monica, Tosca, Mariangela, Varricchio, Attilio, Zicari, Anna Maria, Alfaro, Carlo, Barberi, Salvatore, Becherucci, Paolo, Bernardini, Roberto, Biasci, Paolo, Caffarelli, Carlo, Caldarelli, Valeria, Capristo, Carlo, Castronuovo, Serenella, Chiappini, Elena, Cutrera, Renato, De Castro, Giovanna, De Franciscis, Luca, Decimo, Fabio, Iacono, Iride Dello, Diaferio, Lucia, Di Cicco, Maria Elisa, Di Mauro, Caterina, Di Mauro, Cristina, Di Mauro, Dora, Di Mauro, Francesco, Di Mauro, Gabriella, Doria, Mattia, Falsaperla, Raffaele, Ferraro, Valentina, Fanos, Vassilios, Galli, Elena, Ghiglioni, Daniele Giovanni, Indinnimeo, Luciana, Kantar, Ahmad, Lamborghini, Adima, Licari, Amelia, Lubrano, Riccardo, Luciani, Stefano, Macrì, Francesco, Marseglia, Gianluigi, Martelli, Alberto Giuseppe, Masini, Luigi, Midulla, Fabio, Minasi, Domenico, Miniello, Vito Leonardo, del Giudice, Michele Miraglia, Morandini, Sergio Renzo, Nardini, Germana, Nocerino, Agostino, Novembre, Elio, Pajno, Giovanni Battista, Paravati, Francesco, Piacentini, Giorgio, Piersantelli, Cristina, Pozzobon, Gabriella, Ricci, Giampaolo, Spanevello, Valter, Turra, Renato, Zanconato, Stefania, Borrelli, Melissa, Villani, Alberto, Corsello, Giovanni, Di Mauro, Giuseppe, and Peroni, Diego

Published
2021
Full Text
View/download PDF

41. Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma ®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System.

Author

Ruggiero, Rosanna, Balzano, Nunzia, Nicoletti, Maria Maddalena, di Mauro, Gabriella, Fraenza, Federica, Campitiello, Maria Rosaria, Rossi, Francesco, and Capuano, Annalisa

Subjects
SPINAL muscular atrophy, ORPHAN drugs, RARE diseases, MEDICAL personnel, LIVER failure
Abstract

The recent introduction of the innovative therapy, onasemnogene abeparvovec (Zolgensma®), has revolutionized the spinal muscular atrophy (SMA) therapeutic landscape. Although Zolgensma® therapy has proven to lead to functional improvements in SMA children, some gaps in its safety profile still need to be investigated. To better characterize the Zolgensma® safety profile, we conducted a retrospective observational study, analyzing all the Individual Case Safety Reports (ICSRs) referred to it and collected in the European pharmacovigilance database between 1 January 2019 and 22 September 2023. We found 661 ICSRs related to Zolgensma®, with a growing trend in the annual reporting. The majority of the reports were sent by healthcare professionals and referred to infant females. In more than 90% of the cases, Zolgensma® was the only reported suspected drug. Out of a total of 2744 reported ADRs, increased hepatic enzymes, pyrexia, vomiting, and thrombocytopenia were the most commonly reported adverse reactions. Of these adverse reactions (ADRs), 56.9% were serious, causing or prolonging the patient's hospitalization. A total of 39 ICSRs related to cases with a fatal outcome. Alterations in the heart rhythm, acute hepatic failure, and hepatic cytolysis emerged among the cardiac and hepatic disorders, respectively. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis

Author

Mascolo, Annamaria, primary, Rafaniello, Concetta, additional, di Mauro, Gabriella, additional, Ruggiero, Donatella, additional, Campitiello, Maria Rosaria, additional, Donniacuo, Maria, additional, Berrino, Pasquale Maria, additional, Rossi, Francesco, additional, Paolisso, Giuseppe, additional, and Capuano, Annalisa, additional

Published
2023
Full Text
View/download PDF

45. Sepsis Outcome after Major Abdominal Surgery Does Not Seem to Be Improved by the Use of Pentameric Immunoglobulin IgM: A Single-Center Retrospective Analysis

Author

Perrella, Alessandro, primary, Rinaldi, Luca, additional, Guarino, Ilaria, additional, Bernardi, Francesca Futura, additional, Castriconi, Maurizio, additional, Antropoli, Carmine, additional, Pafundi, Pia Clara, additional, Di Micco, Pierpaolo, additional, Sarno, Marina, additional, Capoluongo, Nicolina, additional, Minei, Giuseppina, additional, Perrella, Marco, additional, Frangiosa, Antonio, additional, and Capuano, Annalisa, additional

Published
2023
Full Text
View/download PDF

46. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19

Author

Capoluongo, Nicolina, primary, Mascolo, Annamaria, additional, Bernardi, Francesca Futura, additional, Sarno, Marina, additional, Mattera, Valentina, additional, di Flumeri, Giusy, additional, Pustorino, Bruno, additional, Spaterella, Micaela, additional, Trama, Ugo, additional, Capuano, Annalisa, additional, and Perrella, Alessandro, additional

Published
2023
Full Text
View/download PDF

47. Thromboembolic Events after COVID-19 Vaccination: An Italian Retrospective Real-World Safety Study

Author

Bernardi, Francesca Futura, primary, Mascolo, Annamaria, additional, Sarno, Marina, additional, Capoluongo, Nicolina, additional, Trama, Ugo, additional, Ruggiero, Rosanna, additional, Sportiello, Liberata, additional, Fusco, Giovanni Maria, additional, Bisogno, Massimo, additional, Coscioni, Enrico, additional, Iervolino, Anna, additional, Di Micco, Pierpaolo, additional, Capuano, Annalisa, additional, and Perrella, Alessandro, additional

Published
2023
Full Text
View/download PDF

49. Retrospective Analysis of a Real-Life Use of Tixagevimab–Cilgavimab Plus COVID19 Antivirals for the Treatment of Early COVID-19

Author

Capoluongo, Nicolina, primary, Mascolo, Annamaria, additional, Bernardi, Francesca futura, additional, Sarno, Marina, additional, Mattera, Valentina, additional, Di flumeri, Giusy, additional, Pustorino, Bruno, additional, Spatarella, Micaela, additional, Trama, Ugo, additional, Capuano, Annalisa, additional, and Perrella, Alessandro, additional

Published
2023
Full Text
View/download PDF

50. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study

Author

Meaidi, Amani, primary, Mascolo, Annamaria, additional, Sessa, Maurizio, additional, Toft-Petersen, Anne Pernille, additional, Skals, Regitze, additional, Gerds, Thomas Alexander, additional, Wessel Skovlund, Charlotte, additional, Morch, Lina Steinrud, additional, Rossi, Francesco, additional, Capuano, Annalisa, additional, Lidegaard, Oejvind, additional, and Torp-Pedersen, Christian, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results